CASI Pharmaceuticals - CASI acquires an early stage CD38 mAb
CASI announced on 17 April 2019 that it had in-licensed the novel CD38 monoclonal antibody TSK011010 from Black Belt Therapeutics. The deal includes a €7m upfront (€5m cash and €2m equity investment) and undisclosed milestones and royalties. The drug is in the pre-IND stage but CASI noted that the IND-enabling studies are complete and it expects to submit IND/IMPD applications at the end of 2019 or early 2020.CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.